OPTINOSE INC. - COMMON STOCK

Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis

13 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Optinose Announces Departure of Chief Financial Officer

03 Jun 2022 07:00:37 By Nasdaq GlobeNewswire

Optinose Reports First Quarter 2022 Financial Results and Operational Updates

12 May 2022 07:00:19 By Nasdaq GlobeNewswire

Optinose Announces Reporting Date for First Quarter 2022 Financial Results

05 May 2022 17:00:00 By Nasdaq GlobeNewswire

Optinose Announces Appointment of R. John Fletcher to the Board

26 Apr 2022 08:00:03 By Nasdaq GlobeNewswire

Optinose to Present at the Needham Virtual Healthcare Conference

08 Apr 2022 08:30:00 By Nasdaq GlobeNewswire

Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

08 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis

07 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Fourth Quarter 2021 Financial Results

04 Mar 2022 14:00:00 By Nasdaq GlobeNewswire

Optinose Announces Appointment of Two New Members to Board of Directors

13 Dec 2021 07:54:10 By Nasdaq GlobeNewswire

Optinose to Present at the Piper Sandler Virtual Healthcare Conference

23 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

18 Nov 2021 16:30:00 By Nasdaq GlobeNewswire

Optinose Announces Closing of $46.0 Million Public Offering of Common Stock

18 Nov 2021 14:00:00 By Nasdaq GlobeNewswire

Optinose Announces Pricing of Public Offering of Common Stock

16 Nov 2021 08:01:59 By Nasdaq GlobeNewswire

Optinose Announces Proposed Public Offering of Common Stock

15 Nov 2021 17:40:53 By Nasdaq GlobeNewswire

Optinose Reports Third Quarter 2021 Financial Results and Recent Operational Highlights

15 Nov 2021 16:26:45 By Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Third Quarter 2021 Financial Results

10 Nov 2021 17:50:01 By Nasdaq GlobeNewswire

Optinose Completes Patient Recruitment in Second Pivotal Trial for XHANCE in Chronic Sinusitis

28 Oct 2021 06:59:00 By Nasdaq GlobeNewswire

Optinose to Present at the Cantor Virtual Global Healthcare Conference

22 Sep 2021 16:15:00 By Nasdaq GlobeNewswire

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

25 Aug 2021 17:00:00 By Nasdaq GlobeNewswire